Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Childhood Choroid Plexus Tumor, Childhood Medulloblastoma, Childhood Pineoblastoma, Childhood Soft Tissue Sarcoma, Childhood Supratentorial Primitive Neuroectodermal Tumor, Neuroblastoma, Osteosarcoma, Retinoblastoma, Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: filgrastim; Biological
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 1 Year to 25 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 9,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Detachment, Rhegmatogenous Retinal Detachment
Interventions: Lamivudine 300 MG, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Macular Edema, Diabetes Mellitus
Interventions: Vitamin E; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes, Diabetic Retinopathy, Diabetic Macular Edema, Diabetic Eye Problems
Interventions: Color fundus photograph, Optical Coherence Tomography (OCT) of the retina, Mydriatic Agent; Diagnostic Test · Drug
Lead sponsor: RETINA-AI Health, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • Houston, Texas

Conditions: AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions: Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5); Device
Lead sponsor: Notal Vision Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, Renal Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Weeks and older
Enrollment: 6,035 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Orange, Florida • Bethesda, Maryland + 2 more

Conditions: Age-related Macular Degeneration
Interventions: Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet; Drug
Lead sponsor: Snyder, Robert W., M.D., Ph.D., P.C.; Individual
Eligibility: 50 Years to 85 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Cerebral Small Vessel Diseases, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, Cerebral Microbleeding, Sporadic White Matter Disease
Interventions: Cilostazol; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions: ALK-001, Placebo; Drug
Lead sponsor: Alkeus Pharmaceuticals, Inc.; Industry
Eligibility: 8 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 11 more

Conditions: Age Related Macular Degeneration, Choroidal Neovascularization, Macular Edema
Interventions: Bevacizumab, verteporfin photodynamic therapy reduced fluence, verteporfin photodynamic therapy standardfluence; Drug · Device
Lead sponsor: California Retina Consultants; Other
Eligibility: 50 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Bakersfield, California • Santa Barbara, California

Conditions: Proliferative Diabetic Retinopathy
Interventions: Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation; Other · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 48
States / cities: Phoenix, Arizona • Loma Linda, California • Palm Springs, California + 42 more

Conditions: Dry Age-related Macular Degeneration
Interventions: PRIMA; Device
Lead sponsor: Science Corporation; Industry
Eligibility: 60 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Palo Alto, California • Miami, Florida • Pittsburgh, Pennsylvania

Conditions: Age-Related Macular Degeneration
Interventions: NG101 AAV gene therapy; Genetic
Lead sponsor: Elisigen, Inc.; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Macular Edema Secondary to Inflammation
Interventions: KSI-101, Sham Comparator; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 55
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 47 more

Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions: Retinal and Choroidal Imaging; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary, Retinal Diseases
Interventions: AAV OPTIRPE65; Biological
Lead sponsor: MeiraGTx UK II Ltd; Industry
Eligibility: 3 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Macular Degeneration
Interventions: Verteporfin Therapy/ Drug: Bevacizumab; Device
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Retinal Vein Occlusion
Interventions: Dexamethasone intravitreal implant, Monthly Ranibizumab; Drug
Lead sponsor: Brian Burke, MPH; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Age-related Macular Degeneration (AMD)
Interventions: No intervention.; Device
Lead sponsor: iHealthScreen Inc; Industry
Eligibility: 50 Years and older
Enrollment: 1,076 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Richmond Hill, New York

Conditions: Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Interventions: Faricimab Injection, sham treatment; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Central Serous Chorioretinopathy
Interventions: Micropulse Laser Treatment, No treatment; Device · Other
Lead sponsor: George Washington University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions: Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin; Drug · Other
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 55 Years to 92 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinitis Pigmentosa
Interventions: CAREN system training; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 25 Years to 100 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

Laser and Antioxidant Treatment of Diabetic Macular Edema

Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device

NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

Dose Ranging Study of Carbidopa-levodopa

Retina is a Marker for Cerebrovascular Heath

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

PRIMA US-Feasibility Study in Atrophic Dry AMD

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

Retinal Imaging in Neurodegenerative Disease

Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD

Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion

Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy

Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

Computer-Assisted Rehabilitation Environment Training After Argus Retinal Prosthesis